The dark side of hope and trust: Constructed expectations and the value-for-money regulation of new medicines

Health Sociology Review

Volumn 20, Issue 4, 2011, Pages 410-422

  Brown, Patrick R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Hope; NICE; Pharmaceuticals; Regulation; Sociology; Uncertainty

Indexed keywords

EID: 84857842632     PISSN: 14461242     EISSN: None     Source Type: Journal    
DOI: 10.5172/hesr.2011.20.4.410     Document Type: Review

References (55)

1. Abraham, J. (1995). Science, politics and the pharmaceutical industry: Controversy and bias in drug regulation. London: UCL Press/Routledge.
2. Abraham, J. (2008). Sociology of pharmaceuticals development and regulation: A realist empirical research programme. Sociology of Health and Illness, 30(6), 869-885.
3. Abraham, J. (2009). The pharmaceutical industry, the state and the NHS. In J. Gabe & M. Calnan (Eds.), The new sociology of the health service (pp. 99-120). London: Routledge.
4. Abraham, J., & Lewis, G. (2000). Regulating medicines in Europe: Competition, expertise and public health. London: Routledge.
5. Abraham, J., & Lewis, G. (2002). Citizenship, medical expertise and the capitalist regulatory state. Sociology, 36(1), 67-88.
6. Alaszewski, A. (2002). The impact of the Bristol Royal Infirmary disaster and inquiry on public services in the UK. Journal of Interprofessional Care, 16(4), 371-378. (Pubitemid 35402138)
7. Ball, T., & Dagger, R. (1991). Ideals and ideologies: A reader. New York: Harper Collins.
8. Black, J. (2008). Constructing and contesting legitimacy and accountability in polycentric regulatory regimes. Regulation & Governance, 2, 137-164.
9. Blume, S. (2010). The artificial ear: Cochlear implants and the culture of deafness. Piscataway, NJ: Rutgers University Press.
10. Britten, N. (2008). Medicines and society: Patients, professionals and the dominance of pharmaceuticals. Basingstoke, UK: Palgrave-Macmillan.
11. Brown, N. (2003). Hope against hype - Accountability in biopasts, presents and futures. Science Studies, 26(2), 3-21.
12. Brown, N., & Webster, A. (2004). New medical technologies and society: Reordering life. Cambridge, UK: Polity.
13. Brown, P. (2009). The phenomenology of trust: A Schutzian analysis of the social construction of knowledge by gynae-oncology patients. Health, Risk and Society, 11(5), 391-407.
14. Brown, P., & Calnan, M. (2010). Political accountability of explicit rationing: Legitimacy problems faced by NICE. Journal of Health Services Research and Policy, 15(2), 65-66.
15. Calman, K., & Hine, D. (1995). A policy framework for commissioning cancer services: A report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. London: Department of Health.
16. Calnan, M., & Rowe, R. (2008). Trust matters in healthcare. Buckingham, UK: Open University Press.
17. Crinson, I. (2004). The politics of regulation within the 'modernized' NHS: The case of beta interferon and the 'cost-effective' treatment of multiple sclerosis. Critical Social Policy, 24(1), 30-49. (Pubitemid 38149829)
18. Department of Health. (1997). The new NHS, modern, dependable. London: HMSO.
19. Department of Health. (1998). A first class service - Quality in the new NHS. London: DoH.
20. Department of Health. (2010). Equity and excellence: Liberating the NHS. London: TSO.
21. Douglas, M. (1992). Risk and blame: Essays in cultural theory. London: Routledge.
22. Dyer, C. (2007). NICE's decision on dementia drugs was 'irrational', court is told. BMJ, 334, 1337.
23. Gilson, L. (2006). Trust relations in health care: Theoretical perspectives and research needs. Journal of Health Organization and Management, 20(5), 359-375. (Pubitemid 44440084)
24. Gramsci, A. (1971). Selections from the prison notebooks of Antonio Gramsci. London: Lawrence Wishart.
25. Habermas, J. (1976). Legitimation crisis. Boston, MA: Beacon Press.
26. Habermas, J. (1984). Theory of communicative action. Reason and the rationalisation of society (Vol. 1). Boston, MA: Beacon.
27. Hall, S. (1983). The problem of ideology - Marxism without guarantees. In B. Matthews (Ed.), Marx: 100 years on. London: Lawrence and Wishart.
28. Ham, C., & Alberti, K. (2002). The medical profession, the public and the government. BMJ, 324, 838-842.
29. Hedgecoe, A. (2004). The politics of personalised medicine: Pharmacogenetics in the clinic. Cambridge, UK: Cambridge University Press.
30. Hortobagyi, G. (2005). Trastuzumab in the treatment of breast cancer. New England Journal of Medicine, 353, 1734-1736. (Pubitemid 41464714)
31. Kennedy, I. (2009). Appraising the value of innovation and other benefits. London: NICE.
32. Luhmann, N. (1979). Trust and power. Chichester, UK: Wiley.
33. Meyer, S., & Ward, P. (2009). Reworking the sociology of trust: Making a semantic distinction between trust and dependence. In S. Lockie, D. Bissell, A. Grieg, M. Hynes, D. Marsh, L. Saha, et al. (Eds.), The future of sociology - Conference proceedings (pp. 1-16). Canberra, ACT: TASA.
34. Möllering, G. (2006). Trust: Reason, routine, reflexivity. Oxford, UK: Elsevier.
35. Moran, M. (2003). The British regulatory state: High modernism and hyper innovation. Oxford, UK: Oxford University Press.
36. NICE. (2006). Final appraisal determination: Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: NICE.
37. NICE. (2009a). About technology appraisals. Accessed October 30, 2009, from http://www.nice.org.uk/aboutnice/whatwedo/abouttechnologyappraisals/ about-technology-appraisals.jsp
38. NICE. (2009b). Report of threshold workshop. London: NICE.
39. Outhwaite, W. (2009). Habermas: A critical introduction. Cambridge, UK: Polity Press.
40. Power, M. (1997). The audit society: Rituals of verification. Oxford, UK: Oxford University Press.
41. Power, M. (2005). The risk management of everything. London: Demos.
42. Rorty, R. (2002). Solidarity or objectivity? In K. Brad Wray (Ed.), Knowledge and inquiry: Readings in epistemology (pp. 422-437). Peterborough, ON: Broadview Press.
43. Rothstein, H. (2006). The institutional origins of risk: A new agenda for risk research. Health, Risk and Society, 8(3), 215-221. (Pubitemid 44275699)
44. Seale, C. (2001). Sporting cancer: Struggle language in news reports with cancer. Sociology of Health and Illness, 23(3), 308-329.
45. Simpson, C. (2004). When hope makes us vulnerable: A discussion of patient provider interactions in the context of hope. Bioethics, 18(5), 428-447. (Pubitemid 39213945)
46. Smith, R. (2005). Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Medicine, 2(5), e138.
47. Sontag, S. (2002). Illness as metaphor and AIDS and its metaphors. London: Penguin.
48. Of NICE and men. (2009, July 7). Wall Street Journal, A14.
49. Weber, M. (1968). Economy and society (Vol. 1). New York: Bedminster.
50. Wilkinson, I. (2005). Suffering: A sociological introduction. Cambridge, UK: Polity.
51. Wilkinson, I. (2010). Risk, vulnerability and everyday life. London: Routledge.
52. Williams, S., Gabe, J., & Davis, P. (2008). The sociology of pharmaceuticals: Progress and prospects. Sociology of Health and Illness, 30(6), 813-824.
53. Zigon, J. (2006). An ethics of hope: Working on the self in contemporary Moscow. Anthropology of East Europe Review, 24(2), 71-80.
54. Zinn, J. (2008). Heading into the unknown: Everyday strategies for managing risk and uncertainty. Health, Risk and Society, 10(5), 439-450.
55. Zizek, S. (2006). Interview in: The children of men. Los Angeles, CA: Universal Pictures.